DxS Expand Their Portfolio Of Cancer Mutation Products, With The Launch Of A PI3K Mutation Detection Kit

News — By on November 11, 2008 at 11:11 am

DxS, a personalised medicine company and market leaders in the provision of companion diagnostics are pleased to announce the addition of a PI3K Mutation Detection Kit to their portfolio of oncogene mutation products. PI3K is a biomarker assessed during the evaluation of the tyrosine kinase inhibitors targeting the EGFR pathway. The PI3K-AKT pathway is activated in a variety of tumour types resulting in cell growth and proliferation.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback